Knight Therapeutics Inc. places on The Globe and Mail’s third-annual Women Lead Here benchmark of executive gender diversity
25 Março 2022 - 11:10AM
Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is
pleased to announce it has been recognized in The Globe and Mail’s
2022 Report on Business Women Lead Here list. This annual editorial
benchmark identifies best-in-class executive gender diversity in
corporate Canada.
Established in 2020 by Report on Business
magazine, the Women Lead Here initiative applies a proprietary
research methodology to determine Canadian corporations with the
highest degree of gender diversity among executive ranks. This
initiative highlights businesses that have made tangible, systemic,
organizational progress related to executive gender parity.
“We are honored to be recognized by The Globe
and Mail as one of Canada’s Women Lead Here,” said Samira Sakhia,
President and Chief Executive Officer of Knight. “At Knight, we
believe that diversity is the over-arching value that we all need
to strive towards. We are proud of the female leadership across our
organization but we know we need to continue on our commitment to
empower women and other minorities in our organization now and into
the future.”
For the 2022 ranking, Report on Business
conducted a journalistic analysis of nearly 500 large publicly
traded Canadian companies, evaluating the ratio of
female-identifying to male-identifying executives in the top three
tiers of executive leadership. The resultant data was applied to a
weighted formula that also factored in company performance,
diversity, and year-to-year change.
In total, 74 companies earned the 2022 Women
Lead Here seal, with a combined average of 46% of executive roles
held by female-identifying individuals.
The full list of 2022 Women Lead Here honourees
can be found in the April issue of Report on Business magazine,
distributed with The Globe and Mail on Saturday, March 26th, and
online now at tgam.ca/WomenLeadHere.
The strategies and ideas of winning companies
will also be showcased at the Women Lead Here webcast, taking place
on March 30, 2022. Event details and registration information are
available at www.globeandmail.com/events.
About The Globe and MailThe
Globe and Mail is Canada’s foremost news media company, leading the
national discussion and causing policy change through brave and
independent journalism since 1844. With our award-winning coverage
of business, politics and national affairs, The Globe and Mail
newspaper reaches 7.1 million readers every week in our print or
digital formats, and Report on Business magazine reaches 2.2
million readers in print and digital every issue. Our investment in
innovative data science means that as the world continues to
change, so does The Globe. The Globe and Mail is owned by
Woodbridge, the investment arm of the Thomson family.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in
Montreal, Canada, is a specialty pharmaceutical company focused on
acquiring or in-licensing and commercializing pharmaceutical
products for Canada and Latin America. Knight owns Biotoscana
Investments S.A., a pan-Latin American specialty pharmaceutical
company. Knight’s Latin American subsidiaries operate under United
Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics
Inc.'s shares trade on TSX under the symbol GUD. For more
information about Knight Therapeutics Inc., please visit the
company's web site at www.gud-knight.com or www.sedar.com.
Forward-Looking Statement
This document contains forward-looking
statements for Knight Therapeutics Inc. and its subsidiaries. These
forward-looking statements, by their nature, necessarily involve
risks and uncertainties that could cause actual results to differ
materially from those contemplated by the forward-looking
statements. Knight Therapeutics Inc. considers the assumptions on
which these forward-looking statements are based to be reasonable
at the time they were prepared but cautions the reader that these
assumptions regarding future events, many of which are beyond the
control of Knight Therapeutics Inc. and its subsidiaries, may
ultimately prove to be incorrect. Factors and risks which could
cause actual results to differ materially from current expectations
are discussed in Knight Therapeutics Inc.'s Annual Report and in
Knight Therapeutics Inc.'s Annual Information Form for the year
ended December 31, 2021, as filed on www.sedar.com. Knight
Therapeutics Inc. disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of
new information or future events, except as required by law.
Investor
Contact: |
|
|
Knight Therapeutics Inc. |
|
|
Samira Sakhia |
|
Arvind Utchanah |
President & Chief Executive
Officer |
|
Chief Financial Officer |
T: 514.484.4483 |
|
T. 598 2626 2344 |
F: 514.481.4116 |
|
|
Email: info@knighttx.com |
|
Email: info@knighttx.com |
Website: www.gud-knight.com |
|
Website: www.gud-knight.com |
Knight Therapeutics (TSX:GUD)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Knight Therapeutics (TSX:GUD)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024